about
Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variantsFrom proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsBioactive Plant Metabolites in the Management of Non-Communicable Metabolic Diseases: Looking at Opportunities beyond the HorizonMacrophage-mediated cholesterol handling in atherosclerosisPCSK9 inhibition: the way forward in the treatment of dyslipidemiaResidual macrovascular risk in 2013: what have we learned?PCSK9 inhibitors in the prevention of cardiovascular diseaseStatin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaTherapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.Novel method for reducing plasma cholesterol: a ligand replacement therapy.Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.Perspectives in Polycystic Ovary Syndrome: From Hair to EternityDyslipidemia in obesity: mechanisms and potential targetsEfficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expressionCharacterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair.New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?Chromatin and beyond: the multitasking roles for SIRT6Relation between proprotein convertase subtilisin/kexin type 9 and directly measured low-density lipoprotein cholesterol.The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.Anti-PCSK9 therapies for the treatment of hypercholesterolemia.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.
P2860
Q24273409-0213A791-F07E-450A-B238-3270A8719F1AQ26741078-81969813-4256-4697-BF50-57DAE728989EQ26771980-A1050E02-6347-4ED0-AD9D-ED84974581BBQ26780405-82A5F1D0-896A-45FA-A12C-431836CF82B1Q26784482-D39DD778-C71E-4F07-977D-AB39D6E84427Q26996039-0FC2AF99-BCEE-47C6-A4C2-7199BDC0BD7DQ28071452-B04F50AE-D8E8-4F70-96F0-307765DDA522Q28083004-7CF23386-71B3-42FA-97B5-DDEEE5576F29Q28275648-0E794EED-4080-4FCC-A854-0EAAD975A788Q33670893-49247D17-7753-4F17-80DA-A276D8358DF3Q33904455-C8C53221-7D51-4024-AC3B-81359C53B126Q34035025-2DB2A32A-631E-49FD-A8F9-B23F10001CDAQ34238694-AFB7BD6E-261C-49A6-976E-62B339C61D16Q34536594-DD0CDBBB-9D7F-478A-99DD-A56360A652F7Q34937512-9E397805-C950-41FE-8447-BB728DCC9CA4Q35194029-C66171A2-F2DF-4D96-BF0E-EC424C4E96E0Q35558371-89150B61-738C-41FC-857A-946A35BBB917Q35664577-1B686EF7-80E0-4DB4-8677-7FC97126F8CDQ35794774-2C2F4E1F-5720-4CA2-B9D6-25FF3CBCDD3CQ35963040-20CFACFD-CBC2-4F32-86B4-105EB5AE006CQ36035643-AA51A781-6F3A-4254-AE2D-1D6753316AA1Q36051650-88F2EFAD-35A0-4782-8A53-480BA5765754Q36196859-A9150C5B-B6C7-453D-9332-A169A2A3D535Q36362512-42245B84-91BB-4473-8A87-70E7B2F6A709Q36716040-520A17B4-F6D0-4550-89E3-AD05C5880113Q36994072-02C61E98-57DD-496C-A4AD-F2445BD9F750Q37034257-182CF800-BB86-48A2-820B-4DB7F94C3513Q37226067-8F248F1A-4C87-48C7-AC21-D12570E8AA4EQ37397710-67E4E169-68BE-4A58-B7BE-0ECBC8F3A6D2Q37405644-74EC5700-1422-4F1F-BE0A-B7C47624E0A2Q37429025-DEF0CD44-603F-4BB5-8524-2C46B7403B64Q37549637-79EBC867-924C-4377-9D5A-39134559F605Q37591725-CB9CB7A1-B267-4079-8C3E-74E54927B1F2Q37693614-72BB5B78-82EA-41F4-8922-15D3F70A3B94Q37705810-72C32182-C960-4550-B19A-C0B490E1F967Q38067460-02992CC2-6E81-477A-B6BE-7E27EFDB79BEQ38075818-73A715C8-1A5C-4ADA-9D6E-089A47E65E03Q38078264-6D71D855-EA39-421F-8E00-847596389FC5Q38089623-025F6BEC-962F-420B-B50C-3106AC263BD7Q38109960-5258D3D9-6794-4A56-BE93-136A532DB249
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The PCSK9 decade
@ast
The PCSK9 decade
@en
The PCSK9 decade
@nl
type
label
The PCSK9 decade
@ast
The PCSK9 decade
@en
The PCSK9 decade
@nl
prefLabel
The PCSK9 decade
@ast
The PCSK9 decade
@en
The PCSK9 decade
@nl
P2093
P2860
P3181
P356
P1476
The PCSK9 decade
@en
P2093
Barbara Sjouke
Benjamin Choque
G Kees Hovingh
Gilles Lambert
John J P Kastelein
P2860
P304
P3181
P356
10.1194/JLR.R026658
P407
P577
2012-12-01T00:00:00Z